180 Life Sciences Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? (Deficit) Equity (Details)

Stockholders’ (Deficit) Equity (Details) - USD ($)									3 Months Ended		9 Months Ended
Stockholders’ (Deficit) Equity (Details) - USD ($)	Jul. 19, 2024	May 13, 2024	Apr. 23, 2024	Mar. 14, 2024	Nov. 28, 2023	Nov. 15, 2023	Oct. 11, 2023	Aug. 09, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Oct. 04, 2024	Sep. 05, 2024	Jun. 30, 2024	Mar. 31, 2024	Feb. 29, 2024	Feb. 16, 2024	Dec. 31, 2023	Aug. 31, 2023	Jun. 30, 2023	Apr. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jul. 31, 2022
Stockholders’ (Deficit) Equity [Line Items]
Common stock shares (in Shares)									1,026,930		1,026,930			57,328					534,719
Aggregate shares of common stock (in Shares)	28,012							35,102
Accounts payable in consideration	$ 96,000
Fair value	5,950
Recognized a gain	$ 36,682
Purchase price per share (in Dollars per share)								$ 12.35	$ 1.95		$ 1.95					$ 1
Percentage of shares outstanding							20.00%
Stockholders’ deficit									$ 3,733,774	$ (149,327)	$ 3,733,774	$ (149,327)			$ (417,987)	$ (954,466)			$ (127,733)		$ 6,715,803		$ 7,139,924	$ 11,343,918
Pre-funded warrants (in Shares)					257,205
Common stock warrants to purchase (in Shares)					477,058
Net proceeds								$ 2,700,000
Additional paid in capital								$ 300,000	$ 135,955,083		$ 135,955,083								130,117,209
Purchaser agreed to pay					$ 830,769
Warrants exercise price (in Dollars per share)					$ 3.23				$ 1.68		$ 1.68
Exercise price (in Dollars per share)									$ 3.23		$ 3.23
Expiration date											Feb. 16, 2029
Stock-based compensation expense									$ 16,456	644,618	$ 274,826	1,753,349
Aggregate gross proceeds										60,624		60,624
Amortization of stock options										583,994		1,692,725
General and administrative expenses									563,361		1,504,768
Research and development expenses									151,138	132,880	455,345	481,027
Unrecognized stock-based compensation expense									216,284		$ 216,284
Recognized over the weighted average remaining vesting period											1 year 4 months 24 days
August 2023 Pre-Funded Warrants [Member]
Stockholders’ (Deficit) Equity [Line Items]
Pre-funded warrants (in Shares)								207,814
August 2023 Common Warrants [Member]
Stockholders’ (Deficit) Equity [Line Items]
Common stock warrants to purchase (in Shares)								242,915
Warrant [Member]
Stockholders’ (Deficit) Equity [Line Items]
Gross proceeds								$ 2,999,606
Maximum [Member]
Stockholders’ (Deficit) Equity [Line Items]
Shares issued under the plan (in Shares)											24,736
Minimum [Member]
Stockholders’ (Deficit) Equity [Line Items]
Shares issued under the plan (in Shares)											223,679
Common Stock [Member]
Stockholders’ (Deficit) Equity [Line Items]
Share price (in Dollars per share)																		$ 0.0001
Stockholders’ deficit									103	$ 35	$ 103	$ 35			$ 95	$ 86			$ 54		$ 28		$ 20	$ 20
General and Administrative Expenses [Member]
Stockholders’ (Deficit) Equity [Line Items]
Stock-based compensation expense									15,156		269,627
Research and Development Expense [Member]
Stockholders’ (Deficit) Equity [Line Items]
Stock-based compensation expense									1,300		5,200
Amendment to the August 2023 Offering [Member]
Stockholders’ (Deficit) Equity [Line Items]
Warrants exercise price (in Dollars per share)					$ 0.0019
Research and development expenses									$ 81,257		$ 248,581
Class K Special Voting Shares [Member]
Stockholders’ (Deficit) Equity [Line Items]
Number of shares (in Shares)											14
Former Board [Member]
Stockholders’ (Deficit) Equity [Line Items]
Common stock shares (in Shares)			63,818
Compensate accrued board of director fees			$ 112,024
Recognized loss			$ 9,230
Nasdaq Capital Market [Member]
Stockholders’ (Deficit) Equity [Line Items]
Stockholders’ equity						$ 2,500,000
Director [Member]
Stockholders’ (Deficit) Equity [Line Items]
Increasing its stockholders’ equity		$ 2,500,000
Common Stock [Member] \| Class K Special Voting Shares [Member]
Stockholders’ (Deficit) Equity [Line Items]
Number of shares (in Shares)				14
Series B Convertible Preferred Stock [Member]
Stockholders’ (Deficit) Equity [Line Items]
Convertible preferred stock (in Shares)													1,000,000
Amendment to August 2023 Offering [Member]
Stockholders’ (Deficit) Equity [Line Items]
Common stock shares (in Shares)																257,205	257,205			242,915		82,668		135,339	16,138
Offering were exercised											$ 489